Kurin, Inc. announces clinical study results of the Kurin Lock™ blood culture initial specimen diversion device at the APIC Annual Conference

SAN DIEGO, Calif.--()--Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today at the 2018 APIC Annual Conference in Minneapolis, MN, new clinical study data supporting the efficacy of their specimen diversion device for blood culture collection. Kurin offers the only FDA 510(k)-cleared blood culture diversion product on the market. The patented Kurin Lock™ automatically diverts approximately 0.15ml of initial blood and potential skin contaminants therein during blood culture collection. When skin microbes enter blood culture samples, false positive test results may misinform physicians and lead to unnecessary medical treatment, risk for patients, and significant costs for the hospital.

“This study focuses on total blood culture contaminants, and not just vacutainer collections. Without stratification, the mentioned results are what a user could expect to reproduce in a 'real world' scenario.”

The director of infection prevention at Bayfront Health in St. Petersburg, Fla., Jared Sutton, MPH, CIC, presented data from a 9-month study of 4,200 blood cultures collected by their phlebotomy and emergency department teams. During the trial, in which Kurin was employed for only 50% of all blood culture collections, the overall contamination rate inclusive of cultures taken both with and without Kurin, dropped by 54% from 2.5% to 1.2%, a statistically significant decline. When limiting the analysis to collections for which Kurin was used, there was only one contamination, which equates to approximately a 90% decrease in the contamination rate. The hospital estimates that each false positive blood culture adds $7,500 in costs, so implementing Kurin would save the hospital over $500,000 annually, after the cost of the product.

Sutton and colleagues reported, “This study focuses on total blood culture contaminants, and not just vacutainer collections. Without stratification, the mentioned results are what a user could expect to reproduce in a 'real world' scenario.”

Bob Rogers, CEO of Kurin, said, “As we have seen elsewhere, this study is additional confirmation that effective diversion of skin contaminants can be accomplished with approximately 0.15ml of blood waste and without requiring clinicians to change their standard practice. The accumulating data proves that Kurin can help hospitals prevent blood culture contamination, even in fast-paced EDs.”

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.

Contacts

Kurin, Inc.
Matt Heindel, 858-752-9514
mattheindel@kurin.com

Recent Stories

RSS feed for Kurin Inc.

Release Summary

New study data presented at APIC demonstrates the success of Kurin® blood culture specimen diversion in reducing contamination at a Florida hospital.

Kurin Inc.